UCB's Global Corporate Website
Welcome to UCB in the United States

Mar

18

Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

Mar

17

Exploring the future of dermatology at AAD 2023

Mar

16

You Speak, We Listen: How Community Voices Drive Our Work in HS

Mar

16

UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa

Mar

15

Building a Community of Trust in Epilepsy & Rare Syndromes

Feb

23

Voices on Value: Building a Sustainable Healthcare System for a Healthier Tomorrow – The Second Annual U.S. Sustainable Access and Pricing Transparency Report

Feb

17

Patient-First, Patient-Focused: Our Purpose and Promise

Feb

10

Partnering With the Dermatology Community to Improve Health Equity

Feb

07

Benjamin Jessie and Kurt Hughes Use Combined 50+ Years in Industry to Create New Experiences and Forums for Colleagues

Jan

30

Collaboration with Duke University Focuses on Health Equity for Adolescents in Uganda